Newsroom
Strive to Deliver Breakthroughs
-
September 02, 2020
Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020
September, 2, 2020, Cambridge, MA, Rotterdam, NL, Shanghai, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, pr...
View more -
August 31, 2020
Harbour BioMed Will Present Its New Platform HBICE™ (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit
August, 31, 2020, Shanghai, China – Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented &nb...
View more -
August 24, 2020
Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases
Cambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has enter...
View more -
August 21, 2020
Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020
HBM’s Bispecific Antibody BCMA X CD3 (HBM7020) has a unique 2+1 format built by the proprietary fully human heavy chain only antibody derived fro...
View more -
August 19, 2020
Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19
Cambridge, MA, Rotterdam, NL, Suzhou CN – August 19, 2020. Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, tod...
View more -
July 31, 2020
Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups
July 31, 2020 — Cambridge, MA, Rotterdam, NL, Suzhou, Shanghai, CN— Harbour BioMed (HBM) , a global clinical stage biopharmaceutical company and Vi...
View more -
July 16, 2020
Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 16th, 2020. Harbour BioMed (HBM), a global clinical stage biopharmaceutical company, today announced...
View more -
July 09, 2020
Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation
HBM has completed raising more than $177M in the first half of 2020 New funding will drive advancement of a global therapeutic portfolio in oncolo...
View more -
June 11, 2020
Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board
Cambridge, MA, Rotterdam, The Netherlands, Suzhou, CN – June 11th, 2020 Harbour BioMed (HBM) announced today the appointment of Dr. Jon Wigginton...
View more -
June 05, 2020
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
CAMBRIDGE, Mass., NORTH CHICAGO, Ill., UTRECHT and ROTTERDAM, The Netherlands, SUZHOU, China, June 5, 2020 – AbbVie (NYSE:ABBV), Harb...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1